WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) is set to deliver a corporate update at the upcoming ThinkEquity Conference on October 30th, where Craig Fraser, the company’s Chairman and CEO, will share significant advancements regarding their leading drug candidate, istaroxime. The presentation is scheduled for 12:30 PM ET, accompanied by one-on-one meetings with investors.
Fraser will provide insights into the recent positive topline results from the Phase 2b SEISMiC Extension Study, focusing on istaroxime’s impact in treating early cardiogenic shock associated with heart failure. This update is expected to underscore Windtree’s strategic direction and outline future milestones.
Istaroxime represents a novel therapeutic approach in cardiac care, functioning through a dual mechanism that targets both systolic and diastolic heart functions. As a positive inotropic agent, istaroxime enhances myocardial contractility by inhibiting the Na+/K+- ATPase, while also promoting myocardial relaxation via the SERCA2a calcium pump, facilitating calcium reuptake in the heart’s sarcoplasmic reticulum.
Previous Phase 2 studies have demonstrated that intravenous administration of istaroxime significantly boosts cardiac performance and stabilizes blood pressure without elevating heart rate or causing arrhythmias, which are common concerns in heart failure treatments.
Windtree’s presentation will likely emphasize the potential of istaroxime to transform treatment paradigms for patients experiencing early cardiogenic shock, marking an important step in the company’s ongoing mission to advance innovative cardiac therapies.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.